Parkinsons
FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
March 30, 2016Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
MRC commits £60m to new research projects
October 7, 2014Research and Development, Sales and Marketing MRC, NHS, Parkinson's, Parkinsons, UCL, experimental medicine challenge
Three new research programmes that aim to deliver a step-change in the understanding of disease by using human volunteers in …
Dementia research ‘achingly slow’
June 20, 2014Research and Development, Sales and Marketing Alzheimer's, Cameron, Parkinson's, Parkinsons, UK, billings, dementia, research
The UK prime minister’s envoy on dementia has described progress on research into the neurodegenerative condition as ‘achingly slow’. Global …
Takeda to buy Envoy Therapeutics
November 7, 2012Research and Development, Sales and Marketing CNS, Envoy, Parkinson's, Parkinsons, Takeda
Takeda Pharmaceutical Company has bought another private US firm, its second in as many months. The Japanese group is paying …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
